Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

By LabMedica International staff writers
Posted on 24 Sep 2026

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias. More...

The pathway combines C2N Diagnostics’ UK Medicines and Healthcare products Regulatory Agency (MHRA)-registered PrecivityAD2 blood test with Cambridge Cognition’s CANTAB Pathway digital touchscreen cognitive assessment platform and The Alzheimer’s Trust’s nationwide phlebotomy and MRI infrastructure. UK-based healthcare professionals can now order both PrecivityAD2 and CANTAB Pathway through The Alzheimer’s Trust.

PrecivityAD2 uses high-resolution mass spectrometry to measure the amyloid beta protein isoforms Aβ42 and Aβ40, calculate the Aβ42/Aβ40 ratio, and quantify the percentage of tau phosphorylated at amino acid 217 (%p-tau217). These measures are combined through a proprietary algorithm to generate the Amyloid Probability Score 2 (APS2), which indicates the likelihood of amyloid plaque pathology. 

The CANTAB Pathway complements the blood test by providing a tiered series of digital cognitive tasks designed to offer progressively deeper insight into a patient’s cognitive function. The platform has also demonstrated sensitivity to blood biomarkers associated with brain amyloid pathology.

PrecivityAD2 achieved MHRA medical device registration in 2025, marking its first in vitro diagnostic approval worldwide, and was subsequently cleared by the U.S. Food and Drug Administration as an aid in the diagnosis of Alzheimer’s disease. In a prospective study published in JAMA involving more than 1,200 patients in primary and specialty care, the clinically validated PrecivityAD2 algorithm achieved a 92% negative predictive value and 91% positive predictive value using a predefined single cutoff. With a two-cutoff approach, both values reached 95%.

Additional evidence supporting the combined use of blood biomarkers and digital cognitive testing comes from a Nature Medicine study conducted across 19 general practitioner clinics in Sweden. In that study, a self-administered digital cognitive assessment combined with the blood biomarker algorithm achieved 90% diagnostic accuracy, compared with 70% accuracy for standard-of-care assessment in general practice.

“The dementia diagnostic challenge in the UK demands bold, collaborative action. By uniting C2N’s pioneering blood biomarker technology, Cambridge Cognition’s clinically validated digital assessments and The Alzheimer’s Trust’s commitment to patient-centred care, this partnership offers a new model for how the healthcare system can meet the scale of the crisis,” said Rob Baker, CEO, Cambridge Cognition.

“The Alzheimer’s Trust can support physician or patient referrals from the whole of the UK, and through our in-house clinical team, either via video or phone calls, support patients through their diagnosis and care pathways according to test results. This personalized, patient-centric approach is a best practice that we have optimized through The Cancer Screening Trust over the last five years,” said Frank Hogarty, CEO, The Alzheimer's Trust and The Cancer Screening Trust.

Related Links
C2N Diagnostics
Cambridge Cognition


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.